Citi analyst Yigal Nochomovitz raised the firm’s price target on Lexicon (LXRX) to $2.10 from $1.90 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect the near-term milestones from Novo Nordisk for LX9851.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX: